Evaluation of a mosaic HIV 1 vaccine in a multicentre randomised double blind placebo controlled phase 1 2a clinical trial APPROACH and in rhesus monkeys.
July 21, 2018
Authors: Barouch DH, et al. Lancet. 2018 Jul 21; 392(10143): 232–243.
Journal: Lancet
Journal Abstract: This phase I/IIa clinical trial evaluated the safety and immunogenicity of adenovirus serotype 26 (Ad26) vector-based HIV-1 vaccine regimens in 393 participants across multiple regions. Results demonstrated that all vaccine regimens were well-tolerated, with the mosaic Ad26 prime/Ad26+gp140 boost regimen showing the strongest immunogenic response, eliciting significant antibody and T-cell responses. A parallel study in rhesus monkeys confirmed the vaccine's potential for protective efficacy, providing critical insights for the development of an HIV-1 vaccine.
Authors: Stefanutti E, Ramani R, Whitener B, Dang H, Bélanger S, Somasundaram L, Cortina K, De Marco A, Tam T, Chai Q, Cameroni E, Gupta R, Schmid MA, Miller JL, Zumsteg AB, Purcell LA, Drewry LL. 0. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies. Microbiol Spectr 0:e00863-25. Journal: Microbiology Spectrum
Antibody Engineering & Therapeutics 2025
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
Authors: Osborn, G., López-Abente, J., Adams, R. et al.
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
